Home › Companies › CHRS

Coherus Oncology, Inc.

CHRS Lead: Approved 1 Biotech Distilled article ↓

Oncology Protein

Most recent annual filing: 2026-03-09

Pipeline (4 active programs)

LOQTORZI

toripalimab

Protein Target: PD-1

Nasopharyngeal Carcinoma Approved Junshi Biosciences
Undisclosed indication Junshi Biosciences

casdozokitug

Protein Target: IL-27

Undisclosed indication

tagmokitug

Protein Target: CCR8

Undisclosed indication

Biotech Distilled coverage (1)

2026-05-20 Coherus Oncology (CHRS) — Scientific Deep Dive for LOQTORZI, Casdozokitug, and Tagmokitug

Articles open on Substack. Some deep dives are subscriber-only.